

Publications

LBI members
2003-2021

Original Articles
2021

1. ***Low SARS-CoV-2 seroprevalence in the Austrian capital after an early governmental lockdown.***
Breyer MK, Breyer-Kohansal R, Hartl S, Kundi M, Weseslindtner L, Stiasny K, Puchhammer-Stöckl E, Schrott A, Födinger M, Binder M, Fiedler M, Wouters EFM, Burghuber OC. Sci Rep 11, 10158 (2021). IF: 3.998.
2. ***Downregulation of DUOX1 function contributes to aging-related impairment of innate airway injury responses and accelerated senile emphysema.***
Schiffers C, Lundblad LKA, Hristova M, Habibovic A, Dustin CM, Daphtary N, Aliyeva M, Seward DJ, Janssen-Heininger YMW, Wouters EFM, Reynaert NL, van der Vliet A. Am J Physiol Lung Cell Mol Physiol. 2021 May 5. PMID: 33951398. IF: 4.418
3. ***Comorbidity clusters in patients with moderate-to-severe OSA.***
Testelmans D, Spruit MA, Vrijsen B, Sastry M, Belge C, Kalkanis A, Gaffron S, Wouters EFM, Buyse B. Sleep Breath. 2021 May 3. PMID: 33942208. IF: 2.162
4. ***A comprehensive antigen production and characterisation study for easy-to-implement, specific and quantitative SARS-CoV-2 serotests.***
Klausberger M, Duerkop M, Haslacher H, Wozniak-Knopp G, Cserjan-Puschmann M, Perkmann T, Lingg N, Aguilar PP, Laurent E, De Vos J, Hofner M, Holzer B, Stadler M, Manhart G, Vierlinger K, Egger M, Milchram L, Gludovacz E, Marx N, Köppl C, Tauer C, Beck J, Maresch D, Grünwald-Gruber C, Strobl F, Satzer P, Stadlmayr G, Vavra U, Huber J, Wahrmann M, Eskandary F, Breyer MK, Sieghart D, Quehenberger P, Leitner G, Strassl R, Egger AE, Irsara C, Griesmacher A, Hoermann G, Weiss G, Bellmann-Weiler R, Loeffler-Ragg J, Borth N, Strasser R, Jungbauer A, Hahn R, Mairhofer J, Hartmann B, Binder NB, Striedner G, Mach L, Weinhäusel A, Dieplinger B, Grebien F, Gerner W, Binder CJ, Grabherr R. EBioMedicine. 2021 Apr 24;67:103348. IF: 5.736
5. ***The prevalence and related factors of fatigue in patients with COPD: a systematic review.***
Ebadi Z, Goërtz YMJ, Van Herck M, Janssen DJA, Spruit MA, Burtin C, Thong MSY, Muris J, Otter J, Looijmans M, Vlasblom C, Bastiaansen J, Prins J, Wouters EFM, Vercoulen JH, Peters JB. Eur Respir Rev. 2021 Apr 13;30(160):200298. IF: 6.22.

6. ***Glutathionylation chemistry promotes interleukin 1 beta-mediated glycolytic reprogramming and pro-inflammatory signaling in lung epithelial cells.***
Aboushousha R, Elko E, Chia SB, Manuel AM, van de Wetering C, van der Velden J, MacPherson M, Erickson C, Reisz JA, D'Alessandro A, Wouters EFM, Reynaert NL, Lam YW, Anathy V, van der Vliet A, Seward DJ, Janssen-Heininger YMW. *FASEB J.* 2021 May;35(5):e21525. IF: 4.966.
7. ***Health Literacy Among Patients With Chronic Lung Disease Entering Pulmonary Rehabilitation and Their Resident Loved Ones.***
Coenjaerds MMJ, Spruit MA, Cleutjens FAHM, Ponds RWHM, Franssen FME, Wouters EFM, Janssen DJA. *J Cardiopulm Rehabil Prev.* 2021 Mar 26. Epub ahead of print. PMID: 33797458. IF: 1.383.
8. ***Healthcare and Societal Costs in Patients with COPD and Breathlessness after Completion of a Comprehensive Rehabilitation Program.***
Verberkt CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, Vanfleteren LEGW, Franssen FME, Groenen MTJ, Wouters EFM, Janssen DJA. *COPD.* 2021 Mar 10:1-24. Epub ahead of print. PMID: 33719787. IF: 2.772.
9. ***Frequency and functional translation of low muscle mass in overweight and obese patients with COPD.***
Machado FVC, Spruit MA, Groenen MTJ, Houben-Wilke S, van Melick PP, Hernandez NA, Schols AMWJ, Pitta F, Wouters EFM, Franssen FME. *Respir Res.* 2021 Mar 25;22(1):93. IF: 4.065.
10. ***Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients.***
Hackner K, Buder A, Hochmair MJ, Strieder M, Grech C, Fabikan H, Burghuber OC, Errhalt P, Filipits M. *Clin Med Insights Oncol.* 2021 Feb 17;15:1179554921993072. IF: 1.077.
11. ***Cost-effectiveness of sustained-release morphine for refractory breathlessness in COPD: A randomized clinical trial.***
Verberkt CA, van den Beuken-van Everdingen MHJ, Dirksen CD, Schols JMGA, Wouters EFM, Janssen DJA. [published online ahead of print, 2021 Feb 10]. *Respir Med.* 2021;179:106330. IF: 3.095.
12. ***Downregulation of epithelial DUOX1 in chronic obstructive pulmonary disease. JCI Insight.***
Schiffers C, van de Wetering C, Bauer RA, Habibovic A, Hristova M, Dustin CM, Lambrichts S, Vacek PM, Wouters EF, Reynaert NL, van der Vliet A. *JCI Insight.* 2021 Jan 25;6(2):e142189. IF: 6.205.

2020

13. ***Markers of disease activity in COPD: an 8-year mortality study in the ECLIPSE cohort.***
Celli B, Locantore N, Yates JC, Bakke P, Calverley PMA, Crim C, Coxson HO, Lomas DA,

- MacNee W, Miller BE, Mullerova H, Rennard SI, Silverman EK, Wouters E, Tal-Singer R, Agusti A, Vestbo J. Eur Respir J. 2020 Dec 10:2001339. Epub ahead of print. IF: 12.339.
14. ***Physiological Changes Differ between Responders and Nonresponders to Pulmonary Rehabilitation in COPD.***
Buekers J, De Boever P, Theunis J, Houben-Wilke S, Vaes AW, Franssen FME, Wouters EFM, Simons S, Aerts JM, Spruit MA. Med Sci Sports Exerc. 2020 Dec 23; Publish Ahead of Print. IF: 4.053.
 15. ***Homeopathic Treatment as an Add-On Therapy May Improve Quality of Life and Prolong Survival in Patients with Non-Small Cell Lung Cancer: A Prospective, Randomized, Placebo-Controlled, Double-Blind, Three-Arm, Multicenter Study.***
Frass M, Lechleitner P, Gründling C, Pirker C, Grasmuk-Siegl E, Domayer J, Hochmair M, Gaertner K, Duscheck C, Muchitsch I, Marosi C, Schumacher M, Zöchbauer-Müller S, Manchanda RK, Schrott A, Burghuber O. Oncologist. [published online ahead of print, 2020 Oct 3]. Oncologist. 2020;10.1002/onco.13548. IF: 5.025.
 16. ***Incorporating Comprehensive Assessment Parameters to Better Characterize and Plan Rehabilitation for Persons with Chronic Obstructive Pulmonary Disease.***
Augustin IML, Spruit MA, Franssen FME, Gaffron S, van Merode F, Wouters EFM. J Am Med Dir Assoc. 2020;21(12):1986-1991.e3. IF: 4.367.
 17. ***Induction of dynamic hyperinflation by expiratory resistance breathing in healthy subjects - an efficacy and safety study.***
Urban MH, Mayr AK, Schmidt I, Margulies E, Grasmuk-Siegl E, Burghuber OC, Funk GC. Exp Physiol. 2021 Feb;106(2):532-543. Epub 2020 Nov 23. IF:2.431.
 18. ***Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial.***
Verberkt CA, van den Beuken-van Everdingen MHJ, Schols JMGA, Hameleers N, Wouters EFM, Janssen DJA. JAMA Intern Med. 2020 Oct 1;180(10):1306-1314. IF: 18.652.
 19. ***Results of the Austrian National Lung Cancer Audit.***
Burghuber, OC, Kirchbacher K, Mohn-Staudner A, Hochmair M, Breyer M.-K, Studnicka M, Mueller M. R, Feurstein P, Schrott A, Lamprecht B, Eckmayr J, Renner F, Bolitschek J, Pohl W, Schenk P, Errhalt P, Cerkl P, Baumgartner B, Kneussl M, Hartl S. Clin Med Insights Oncol. 2020 Sep 10;14:1179554920950548. IF: 1.077.
 20. ***Reduced vitamin K status as a potentially modifiable risk factor of severe COVID-19.***
Dofferhoff ASM, Piscaer I, Schurgers LJ, Visser MPJ, van den Ouweland JMW, de Jong PA, Gosens R, Hackeng TM, van Daal H, Lux P, Maassen C, Karssemeijer EGA, Vermeer C, Wouters EFM, Kistemaker LEM, Walk J, Janssen R. [published online ahead of print, 2020 Aug 27]. Clin Infect Dis. 2020;ciaa1258. IF: 8.313.
 21. ***Quality of Life and Limitations in Daily Life of Stable COPD Outpatients in a Real-World Setting in Austria - Results from the CLARA Project.***
Horner A, Burghuber OC, Hartl S, Studnicka M, Merkle M, Olschewski H, Kaiser B,

- Wallner EM, Lamprecht B. *Int J Chron Obstruct Pulmon Dis*. 2020 Jul 12;15:1655-1663. IF: 3.157.
22. ***Effects of roflumilast on arterial stiffness in COPD (ELASTIC): A randomized trial.***
Urban MH, Kreibich N, Gleiss A, Funk GC, Hartl S, Burghuber OC. [published online ahead of print, 2020 Jul 28]. *Respirology*. 2020;10.1111/resp.13914. IF: 4.880.
 23. ***Skin autofluorescence: early sign of lung function deterioration?***
Wouters EFM, Reynaert NL. *ERJ Open Res*. 2020;6(2):00368-2020. Published 2020 Jul 20. IF: 3.350.
 24. ***Side by side comparison of three fully automated SARS-CoV-2 antibody assays with a focus on specificity.***
Perkmann T, Perkmann-Nagele N, Breyer MK, Breyer-Kohansal R, Burghuber OC, Hartl S, Aletaha D, Sieghart D, Quehenberger P, Marculescu R, Mucher P, Strassl R, Wagner OF, Binder CJ, Haslacher H. *Clin Chem*. 2020 Aug 10:hvaa198. IF: 7.292.
 25. ***Factors Associated with Low Lung Function in Different Age Bins in the General Population.***
Breyer-Kohansal R, Faner R, Breyer MK, Ofenheimer A, Schrott A, Studnicka M, Wouters EFM, Burghuber OC, Hartl S, Agusti A. *Am J Respir Crit Care Med* 2020;202(2):292-296. IF: 17.452.
 26. ***Atrial fibrillation: a risk factor for unfavourable outcome in COVID-19? A case report.***
Schnaubelt S, Breyer MK, Siller-Matula J, Domanovits H. *Eur Heart J Case Rep*. 2020 Jun 24;4(F11):1-6. IF: 24.889.
 27. ***Reference charts for body composition parameters by dual-energy X-ray absorptiometry in European children and adolescents aged 6 to 18 years-Results from the Austrian LEAD (Lung, hEart, sociAl, boDy) cohort.***
Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Franssen FME, Wouters EFM, Breyer MK. *Pediatr Obes*. 2021;16(1):e12695. IF: 3.429.
 28. ***Marked differences in prediabetes- and diabetes-associated comorbidities between men and women-Epidemiological results from a general population-based cohort aged 6-80 years -The LEAD (Lung, hEart, sociAl, boDy) study.***
Breyer MK, Ofenheimer A, Altziebler J, Hartl S, Burghuber OC, Studnicka M, Purin D, Heinzle C, Drexel H, Franssen FME, Wouters EFM, Harreiter J, Kautzky-Willer A, Breyer-Kohansal R. *Eur J Clin Invest*. 2020;50(3):e13207. IF: 3.481.
 29. ***Blood eosinophil count in the general population: typical values and potential confounders.***
Hartl S, Breyer MK, Burghuber OC, Ofenheimer A, Schrott A, Urban MH, Agusti A, Studnicka M, Wouters EFM, Breyer-Kohansal R. *Eur Respir J*. 2020;1901874. IF: 12.339.
 30. ***Reference values of body composition parameters and visceral adipose tissue (VAT) by DXA in adults aged 18-81 years-results from the LEAD cohort.***

Ofenheimer A, Breyer-Kohansal R, Hartl S, Burghuber OC, Krach F, Schrott A, Wouters EFM, Franssen FME, Breyer MK. Eur J Clin Nutr 2020;i. IF: 3.291.

2019

31. ***The European COPD audit: Adherence to guidelines, readmission risk and hospital care for acute exacerbations in Austria.***
Breyer-Kohansal R, Hartl S, Breyer MK, Schrott A, Studnicka M, Neunhäuserer D, Fülöp G, Burghuber OC. Wien Klin Wochenschr 2019;131(5–6):97–103. IF: 1.323.
32. ***The LEAD (Lung, Heart, Social, Body) Study: Objectives, Methodology, and External Validity of the Population-Based Cohort Study.***
Breyer-Kohansal R, Hartl S, Burghuber OC, Urban M, Schrott A, Agusti A, Sigsgaard T, Vogelmeier C, Wouters E, Studnicka M, Breyer MK. J Epidemiol 2019;29(8):315–24. IF: 7.707.
33. ***EGFR Mutations in Cell-free Plasma DNA from Patients with Advanced Lung Adenocarcinoma: Improved Detection by Droplet Digital PCR.***
Buder A, Setinek U, Hochmair MJ, Schwab S, Kirchbacher K, Keck A, Burghuber OC, Pirker R, Filipits M. Target Oncol 2019;14(2):197–203. IF: 4.036.
34. ***Impact of afatinib dose modification on safety and effectiveness in patients with EGFR mutation-positive advanced NSCLC: Results from a global real-world study (RealGiDo).***
Halmos B, Tan E-H, Soo RA, et al. Lung Cancer 2019;127:103–11. IF: 4.702.
35. ***Chronic Airway Diseases Early Stratification (CADSET): a new ERS Clinical Research Collaboration.***
Agusti A, Faner R, Donaldson G, Heuvelin E, Breyer-Kohansal R, Melén E, Maitland-van der Zee AH, Vestbo J, Allinson JP, Vanfleteren LEGW, van den Berge M, Adcock IM, Lahousse L, Brusselle G, Wedzicha JA; on behalf of the CADSET Clinical Research Collaboration; Current members of the CADSET Clinical Research Collaboration. Eur Respir J. 2019. IF: 12.339.
36. ***Liquid-Biopsy-Based Identification of EGFR T790M Mutation-Mediated Resistance to Afatinib Treatment in Patients with Advanced EGFR Mutation-Positive NSCLC, and Subsequent Response to Osimertinib.***
Hochmair MJ, Buder A, Schwab S, et al. Target Oncol 2019;14(1):75–83. IF: 4.036.

2018

37. ***Immune cell landscape in therapy-naïve squamous cell and adenocarcinomas of the lung.*** Brcic L, Stanzer S, Krenbek D, et al. Virchows Arch 2018;472(4):589–98.
38. ***Cell-Free Plasma DNA-Guided Treatment With Osimertinib in Patients With Advanced EGFR-Mutated NSCLC.***

- Buder A, Hochmair MJ, Schwab S, et al. *J Thorac Oncol* 2018;13(6):821–30.
39. ***Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer.***
Camidge DR, Kim HR, Ahn MJ, et al. *N Engl J Med* 2018;379(21):2027–39.
 40. ***Fatale immunmedierte organisierende Pneumonie unter Pembrolizumab - Therapie eines pulmonalen Adenokarzinoms. RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgeb Verfahren.***
Gasser S, Krenbek D, Hochmair M. 2018;190(12):1161–3.
 41. ***Bronchoscopic Thermal Vapor Ablation: Best Practice Recommendations from an Expert Panel on Endoscopic Lung Volume Reduction.***
Gompelmann D, Shah PL, Valipour A, Herth FJF. *Respiration* 2018;95(6):1–9.
 42. ***Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.***
Hochmair M. *Target Oncol* 2018;13(3):269–85.
 43. ***Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer: an observational study***
Hochmair MJ, Morabito A, Hao D, et al. *Futur Oncol* 2018;14(27):2861–74.
 44. ***Correction to: Medical Treatment Options for Patients with Epidermal Growth Factor Receptor Mutation-Positive Non-Small Cell Lung Cancer Suffering from Brain Metastases and/or Leptomeningeal Disease.***
Hochmair MJ. *Target Oncol* 2018;13(5):667–667.
 45. ***First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer.***
Horn L, Mansfield AS, Szczesna A, et al. *N Engl J Med* 2018;379(23):2220–9.
 46. ***Phenotypes of COPD in an Austrian population: National data from the POPE study.***
Reiger G, Zwick R, Lamprecht B, Kähler C, Burghuber OC, Valipour A. *Wien Klin Wochenschr* 2018;130(11–12):382–9.
 47. ***Valve therapy in patients with emphysematous type of chronic obstructive pulmonary disease (COPD): from randomized trials to patient selection in clinical practice.***
Valipour A. *J Thorac Dis* 2018;10(S23):S2780–96.
 48. ***Long-term safety of bilateral targeted lung denervation in patients with COPD.***
Valipour A, Asadi S, Pison C, et al. *Int J Chron Obstruct Pulmon Dis* 2018;Volume 13:2163–72.

2017

49. Beeh KM, Burgel P-R, Franssen FME, et al. *How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?* Am J Respir Crit Care Med 2017;196(2):139–49.
50. Buess M, Schilter D, Schneider T, et al. *Treatment of COPD Exacerbation in Switzerland: Results and Recommendations of the European COPD Audit.* Respiration 2017;94(4):355–65.
51. Gómez López A, Luján RG, De Pablo Gafas A, et al. *First use of Amplatzer device for bronchopleural fistula after lung transplantation.* Thorax 2017;668–70.
52. Hochmair MJ, Schwab S, Burghuber OC, Krenbek D, Prosch H. *Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy.* Lung Cancer 2017;113:4–6.
53. Koblizek V, Milenkovic B, Barczyk A, et al. *Phenotypes of COPD patients with a smoking history in Central and Eastern Europe: the POPE Study.* Eur Respir J 2017;49(5):1601446.
54. Lopez-Campos JL, Castro-Acosta A, Pozo-Rodriguez F, Hartl S, Roberts CM. *Accuracy of COPD Diagnosis During an Admission: The European Perspective.* Chest 2017;151(6):1396–7.
55. Slebos D-J, Shah PL, Herth FJF, Valipour A. *Endobronchial Valves for Endoscopic Lung Volume Reduction: Best Practice Recommendations from Expert Panel on Endoscopic Lung Volume Reduction.* Respiration 2017;93(2):138–50.
56. Tudoric N, Koblizek V, Miravittles M, et al. *GOLD 2017 on the way to a phenotypic approach? Analysis from the Phenotypes of COPD in Central and Eastern Europe (POPE) Cohort.* Eur Respir J 2017;49(4):1602518.
57. Urban M, Eickhoff P, Funk G-C, Burghuber OC, Wolzt M, Valipour A. *Increased brachial intima-media thickness is associated with circulating levels of asymmetric dimethylarginine in patients with COPD.* Int J Chron Obstruct Pulmon Dis 2017;12:169–76.

2016

58. Gompelmann D, Eberhardt R, Schuhmann M, et al. *Lung Volume Reduction with Vapor Ablation in the Presence of Incomplete Fissures: 12-Month Results from the STEP-UP Randomized Controlled Study.* Respiration 2016;92(6):397–403.
59. Hartl S, Lopez-Campos JL. *Readmission in COPD patients: should we consider it a marker of quality of care or a marker of a more severe disease with a worse prognosis?* Eur Respir J 2016;48(1):281–2.

60. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. *Risk of death and readmission of hospital-admitted COPD exacerbations: European COPD Audit*. Eur Respir J 2016;47(1):113–21.
61. Herth FJF, Valipour A, Shah PL, et al. *Segmental volume reduction using thermal vapour ablation in patients with severe emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial*. Lancet Respir Med 2016;4(3):185–93.
62. Neunhäuserer D, Steidle-Kloc E, Weiss G, et al. *Supplemental Oxygen During High-Intensity Exercise Training in Nonhypoxemic Chronic Obstructive Pulmonary Disease*. Am J Med 2016;129(11):1185–93.
63. Ruparel M, López-Campos JL, Castro-Acosta A, Hartl S, Pozo-Rodriguez F, Roberts CM. *Understanding variation in length of hospital stay for COPD exacerbation: European COPD audit*. ERJ Open Res 2016;2(1):00034–2015.
64. Shah PL, Gompelmann D, Valipour A, et al. *Thermal vapour ablation to reduce segmental volume in patients with severe emphysema: STEP-UP 12 month results*. Lancet Respir Med 2016;4(9):e44–5.
65. Valipour A. *Endoscopic valve therapy for emphysema: Patient selection as the Holy Grail to success*. Respirology 2016;21(7):1148–9.
66. Valipour A, Slebos D-JJ, Herth FJ, et al. *Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results from the IMPACT Study*. Am J Respir Crit Care Med 2016;194(9):1073–82.
67. Zbozinkova Z, Barczyk A, Tkacova R, et al. *POPE study: Rationale and methodology of a study to phenotype patients with COPD in central and Eastern Europe*. Int J COPD 2016;11(1):611–22.

2015

68. López-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. *Antibiotic Prescription for COPD Exacerbations Admitted to Hospital: European COPD Audit*. PLoS One 2015;10(4):e0124374.
69. Potura E, Lindner G, Biesenbach P, et al. *An acetate-buffered balanced crystalloid versus 0.9% saline in patients with end-stage renal disease undergoing cadaveric renal transplantation: A prospective randomized controlled trial*. Anesth Analg 2015;120(1):123–9.
70. Saleh A, López-Campos JL, Hartl S, Pozo-Rodríguez F, Roberts CM. *The Effect of Incidental Consolidation on Management and Outcomes in COPD Exacerbations: Data*

from the European COPD Audit. PLoS One 2015;10(7):e0134004.

71. Slebos D-JJ, Klooster K, Koegelenberg CFNN, et al. *Targeted lung denervation for moderate to severe COPD: a pilot study*. Thorax 2015;70(5):411–9.
72. Urban M, Burghuber OC, Dereci C, et al. *Tobacco addiction and smoking cessation in Austrian migrants: a cross-sectional study*. BMJ Open 2015;5(6):e006510–e006510.
73. Valipour A, Shah PL, Gesierich W, et al. *Patterns of Emphysema Heterogeneity*. Respiration 2015;90(5):402–11.

2014

74. Breyer M-K, Spruit MA, Hanson CK, et al. *Prevalence of Metabolic Syndrome in COPD Patients and Its Consequences*. PLoS One 2014;9(6):e98013.
75. Gompelmann D, Herth FJF, Slebos DJ, et al. *Pneumothorax following Endobronchial Valve Therapy and Its Impact on Clinical Outcomes in Severe Emphysema*. Respiration 2014;87(6):485–91.
76. Köhnlein T, Windisch W, Köhler D, et al. *Non-invasive positive pressure ventilation for the treatment of severe stable chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial*. Lancet Respir Med 2014;2(9):698–705.
77. Lindner G, Funk G-C, Leichtle AB, et al. *Impact of proton pump inhibitor use on magnesium homeostasis: a cross-sectional study in a tertiary emergency department*. Int J Clin Pract 2014;68(11):1352–7.
78. Lindner G, Doberer D, Schwarz C, Schneeweiss B, Funk G-C. *Evaporation of free water causes concentrational alkalosis in vitro*. Wien Klin Wochenschr 2014;126(7–8):201–7.
79. Lindner G, Funk GC, Pfortmueller CA, et al. *D-dimer to rule out pulmonary embolism in renal insufficiency*. Am J Med 2014;127(4):343–7.
80. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. *Variability of hospital resources for acute care of COPD patients: the European COPD Audit*. Eur Respir J 2014;43(3):754–62.
81. Pertl D, Eisenmann A, Holzer U, Renner A-T, Valipour A. *Effectiveness and efficacy of minimally invasive lung volume reduction surgery for emphysema*. GMS Health Technol Assess 2014;10:Doc01.
82. Pfortmueller CA, Funk G-C, Leichtle AB, et al. *Electrolyte Disorders and In-Hospital Mortality during Prolonged Heat Periods: A Cross-Sectional Analysis*. PLoS One 2014;9(3):e92150.

83. Pfortmueller CA, Wiemann C, Funk G-C, et al. *Hypoglycemia is associated with increased mortality in patients with acute decompensated liver cirrhosis*. J Crit Care 2014;29(2):316.e7-316.e12.
84. Spruit MA, Pitta F, Garvey C, et al. *Differences in content and organisational aspects of pulmonary rehabilitation programmes*. Eur Respir J 2014;43(5):1326–37.
85. Urban MH, Valipour A, Kiss D, Eickhoff P, Funk GC, Burghuber OC. *Soluble receptor of advanced glycation end-products and endothelial dysfunction in COPD*. Respir Med 2014;108(6):891–7.
86. Urban MH, Ay L, Funk GC, et al. *Insulin resistance may contribute to vascular dysfunction in patients with chronic obstructive pulmonary disease*. Wien Klin Wochenschr 2014;126(3–4):106–12.
87. Valipour A, Herth FJF, Burghuber OC, et al. *Target lobe volume reduction and COPD outcome measures after endobronchial valve therapy*. Eur Respir J 2014;43(2):387–96.
88. Valipour A, Herth FJ, Eberhardt R, et al. *Design of the randomized, controlled sequential staged treatment of emphysema with upper lobe predominance (STEP-UP) study*. BMC Pulm Med 2014;14(1):190.
89. Vanfleteren LEGW, Kocks JWH, Stone IS, et al. *Moving from the Oslerian paradigm to the postgenomic era: Are asthma and COPD outdated terms?* Thorax 2014;69(1):72–9.

2013

90. Arampatzis S, Funk G-C, Leichtle AB, et al. *Impact of diuretic therapy-associated electrolyte disorders present on admission to the emergency department: a cross-sectional analysis*. BMC Med 2013;11(1):83.
91. Arampatzis S, Gaetcke L-M, Funk G-C, et al. *Diuretic-induced hyponatremia and osteoporotic fractures in patients admitted to the emergency department*. Maturitas 2013;75(1):81–6.
92. Fazekas AS, Funk G-C, Klobassa DS, et al. *Evaluation of 36 formulas for calculating plasma osmolality*. Intensive Care Med 2013;39(2):302–8.
93. Firlinger I, Stubenberger E, Müller MR, Burghuber OC, Valipour A. *Endoscopic One-Way Valve Implantation in Patients With Prolonged Air Leak and the Use of Digital Air Leak Monitoring*. Ann Thorac Surg 2013;95(4):1243–9.
94. Funk GC, Bauer P, Burghuber OC, et al. *Prevalence and prognosis of COPD in critically ill patients between 1998 and 2008*. Eur Respir J 2013;41(4):792–9.

95. Gompelmann D, Eberhardt R, Ernst A, et al. *The localized inflammatory response to bronchoscopic thermal vapor ablation*. Respiration 2013;86(4):324–31.
96. Kneidinger N, Funk GC, Lindner G, Drolz A, Schenk P, Fuhrmann V. *Unmeasured anions are associated with short-term mortality in patients with hypoxic hepatitis*. Wien Klin Wochenschr 2013;125(15–16):474–80.
97. Lindner G, Pfortmueller CA, Funk G-C, Leichtle AB, Fiedler GM, Exadaktylos AK. *High-Sensitive Troponin Measurement in Emergency Department Patients Presenting with Syncope: A Retrospective Analysis*. PLoS One 2013;8(6):e66470.
98. Lindner G, Schwarz C, Grüssing H, Kneidinger N, Fazekas A, Funk G-C. *Rising serum sodium levels are associated with a concurrent development of metabolic alkalosis in critically ill patients*. Intensive Care Med 2013;39(3):399–405.
99. Lopez-Campos JL, Hartl S, Pozo-Rodriguez F, Roberts CM. *European COPD Audit: Design, organisation of work and methodology*. Eur Respir J 2013;41(2):270–6.
100. Pfortmueller CA, Funk GC, Marti G, et al. *Diagnostic performance of high-sensitive troponin T in patients with renal insufficiency*. Am J Cardiol 2013;112(12):1968–72.
101. Roberts CM, Lopez-Campos JL, Pozo-Rodriguez F, Hartl S. *European hospital adherence to GOLD recommendations for chronic obstructive pulmonary disease (COPD) exacerbation admissions: Table 1*. Thorax 2013;68(12):1169–71.

2012

102. Arampatzis S, Frauchiger B, Fiedler G-M, et al. *Characteristics, Symptoms, and Outcome of Severe Dysnatremias Present on Hospital Admission*. Am J Med 2012;125(11):1125.e1-1125.e7.
103. Arampatzis S, Lindner G, Irmak F, Funk G-C, Zimmermann H, Exadaktylos AK. *Geriatric urolithiasis in the emergency department: risk factors for hospitalisation and emergency management patterns of acute urolithiasis*. BMC Nephrol 2012;13(1):117.
104. Breyer M-K, Rutten EPA, Spruit MA, Hop WCJ, Postma DS, Wouters EFM. *Systemic Inflammation in Patients with Chronic Obstructive Pulmonary Disease: Results from the Cosmic Study*. Open J Respir Dis 2012;02(03):63–72.
105. Breyer M-K, Rutten EPA, Locantore NW, Watkins ML, Miller BE, Wouters EFM. *Dysregulated adipokine metabolism in chronic obstructive pulmonary disease*. Eur J Clin Invest 2012;42(9):983–91.

106. Fazekas AS, Wewalka M, Zauner C, Funk G-C. *Carboxyhemoglobin levels in medical intensive care patients: a retrospective, observational study*. Crit Care 2012;16(1):R6.
107. Gompelmann D, Heussel CP, Eberhardt R, et al. *Efficacy of bronchoscopic thermal vapor ablation and lobar fissure completeness in patients with heterogeneous emphysema*. Respiration 2012;83(5):400–6.
108. Hartl S. *The European COPD Audit: a pilot experience of 16 European countries*. Pneumonol Alergol Pol 2012;80(6):501–4.
109. Herth FJF, Noppen M, Valipour A, et al. *Efficacy predictors of lung volume reduction with Zephyr valves in a European cohort*. Eur Respir J 2012;39(6):1334–42.
110. Herth FJ, KM B, Egan JJ, et al. *Characterization of outcomes 1 year after endoscopic thermal vapor ablation for patients with heterogeneous emphysema*. Int J Chron Obstruct Pulmon Dis 2012;7:397.
111. Lindner G, Schwarz C, Funk G-C. *Osmotic diuresis due to urea as the cause of hypernatraemia in critically ill patients*. Nephrol Dial Transplant 2012;27(3):962–7.
112. Magnussen H, Kramer MR, Kirsten A-M, et al. *Effect of fissure integrity on lung volume reduction using a polymer sealant* in advanced emphysema*. Thorax 2012;67(4):302–8.
113. Snell G, Herth FJF, Hopkins P, et al. *Bronchoscopic thermal vapour ablation therapy in the management of heterogeneous emphysema*. Eur Respir J 2012;39(6):1326–33.
114. Valipour A, Kramer MR, Stanzel F, et al. *Physiological Modeling of Responses to Upper Versus Lower Lobe Lung Volume Reduction in Homogeneous Emphysema*. Front Physiol 2012;3:387.

2011

115. Breyer M-K, Rutten EPA, Vernooy JHJ, et al. *Gender differences in the adipose secretome system in chronic obstructive pulmonary disease (COPD): A pivotal role of leptin*. Respir Med 2011;105(7):1046–53.
116. Faybik P, Hetz H, Mitterer G, et al. *Regional citrate anticoagulation in patients with liver failure supported by a molecular adsorbent recirculating system*. Crit Care Med 2011;39(2):273–9.
117. Funk G-C, Breyer M-K, Burghuber OC, et al. *Long-term non-invasive ventilation in COPD after acute-on-chronic respiratory failure*. Respir Med 2011;105(3):427–34.
118. Locker GJ, Fuchs E-M, Worel N, et al. *Whole Body Hyperthermia by Extracorporeal Circulation in Spontaneously Breathing Sarcoma Patients: Hemodynamics and Oxygen Metabolism*. Int J Artif Organs 2011;34(11):1085–94.

119. Randerath WJ, Verbraecken J, Andreas S, et al. *Non-CPAP therapies in obstructive sleep apnoea*. Eur Respir J 2011;37(5):1000–28.
120. Valipour A, Lavie P, Lothaller H, Mikulic I, Burghuber OC. *Sleep profile and symptoms of sleep disorders in patients with stable mild to moderate chronic obstructive pulmonary disease*. Sleep Med 2011;12(4):367–72.

2010

121. Breyer M-K, Breyer-Kohansal R, Funk G-C, et al. *Nordic Walking improves daily physical activities in COPD: a randomised controlled trial*. Respir Res 2010;11(1):112.
122. Eickelberg O, Laurent G, Nicod LP, Hartl S, Siafakas NM. *European Respiratory Society MD PhD programme in respiratory science*. Eur Respir J 2010;36(2):229–30.
123. Funk G-C, Anders S, Breyer M-K, et al. *Incidence and outcome of weaning from mechanical ventilation according to new categories*. Eur Respir J 2010;35(1):88–94.
124. Lindner G, Funk G-C, Lassnigg A, et al. *Intensive care-acquired hypernatremia after major cardiothoracic surgery is associated with increased mortality*. Intensive Care Med 2010;36(10):1718–23.
125. Rutten EPA, Breyer MK, Spruit MA, et al. *Abdominal fat mass contributes to the systemic inflammation in chronic obstructive pulmonary disease*. Clin Nutr 2010;29(6):756–60.
126. Walch A, Meshkat M, Vogelsang H, et al. *Long-term outcome in patients with ulcerative colitis treated with intravenous cyclosporine A is determined by previous exposure to thiopurines*. J Crohn's Colitis 2010;4(4):398–404.

2009

127. Breyer M-K, Spruit MA, Celis APM, Rutten EPA, Janssen PP, Wouters EFM. *Highly elevated C-reactive protein levels in obese patients with COPD: A fat chance?* Clin Nutr 2009;28(6):642–7.
128. Cekici L, Valipour A, Kohansal R, Burghuber OC. *Short-term effects of inhaled salbutamol on autonomic cardiovascular control in healthy subjects: a placebo-controlled study*. Br J Clin Pharmacol 2009;67(4):394–402.
129. Funk G-C, Kirchheiner K, Chris Burghuber O, Hartl S. *BODE index versus GOLD classification for explaining anxious and depressive symptoms in patients with COPD – a cross-sectional study*. Respir Res 2009;10(1):1.
130. Kaufmann M, Hartl S, Geyer K, Breyer MK, Burghuber OC. *Measuring FEV6 for detecting early airway obstruction in the primary care setting*. Respiration 2009;78(2):161–7.

131. Kohansal R, Martinez-Cambor P, Agustí A, Buist AS, Mannino DM, Soriano JB. *The Natural History of Chronic Airflow Obstruction Revisited*. Am J Respir Crit Care Med 2009;180(1):3–10.
132. Kohansal R, Soriano JB, Agusti A. *Investigating the Natural History of Lung Function: facts, pitfalls, and opportunities*. Chest 2009;135(5):1330–41.
133. Oschatz E, Prosch H, Kohansal R, Valipour A, Mostbeck G. *COPD and Osteoporosis: Detection and Grading of Vertebral Fractures on Lateral Chest Radiography*. J Thorac Imaging 2009;24(3):212–5.
134. Pitta F, Breyer MK, Hernandez NA, et al. *Comparison of daily physical activity between COPD patients from Central Europe and South America*. Respir Med 2009;103(3):421–6.
135. Zwick RH, Burghuber OC, Dovjak N, et al. *Der Effekt von einem Jahr ambulanter pneumologischer Rehabilitation auf Patienten mit COPD*. Wien Klin Wochenschr 2009;121(5–6):189–95.

2008

136. Eickhoff P, Valipour A, Kiss D, et al. *Determinants of Systemic Vascular Function in Patients with Stable Chronic Obstructive Pulmonary Disease*. Am J Respir Crit Care Med 2008;178(12):1211–8.
137. Funk G-C, Lang I, Schenk P, Valipour A, Hartl S, Burghuber OC. *Left Ventricular Diastolic Dysfunction in Patients With COPD in the Presence and Absence of Elevated Pulmonary Arterial Pressure*. Chest 2008;133(6):1354–9.
138. Valipour, Arschang, Ruis M, Burghuber OC. *Journal für Hypertonie*. J für Hypertonie 2008;12(2):31–3.
139. Valipour A, Schreder M, Wolzt M, et al. *Circulating vascular endothelial growth factor and systemic inflammatory markers in patients with stable and exacerbated chronic obstructive pulmonary disease*. Clin Sci 2008;115(7):225–32.
140. Vonbank K, Funk GC, Marzluf B, et al. *Abnormal pulmonary arterial pressure limits exercise capacity in patients with COPD*. Wien Klin Wochenschr 2008;120(23–24):749–55.

2007

141. Eisenburger P, Funk GC, Burda G, Sterz FR, Laggner AN, Herkner H. *Gas concentrations in expired air during basic life support using different ratios of compression to ventilation*. Resuscitation 2007;73(1):115–22.

142. Holzinger U, Kitzberger R, Fuhrmann V, Funk GC, Madl C, Ratheiser K. *Correlation of calculated indices of insulin resistance (QUICKI and HOMA) with the euglycaemic hyperinsulinaemic clamp technique for evaluating insulin resistance in critically ill patients.* Eur J Anaesthesiol 2007;24(11):966–70.
143. Kneidinger N, Lindner G, Fuhrmann V, et al. *Acute phase proteins do not account for unmeasured anions in critical illness.* Eur J Clin Invest 2007;37(10):820–5.
144. Lindner G, Funk GC, Schwarz C, et al. *Hypernatremia in the Critically Ill Is an Independent Risk Factor for Mortality.* Am J Kidney Dis 2007;50(6):952–7.
145. Nava S, Sturani C, Hartl S, et al. *End-of-life decision-making in respiratory intermediate care units: A European survey.* Eur Respir J 2007;30(1):156–64.
146. Valipour A, Lothaller H, Rauscher H, Zwick H, Burghuber OC, Lavie P. *Gender-related differences in symptoms of patients with suspected breathing disorders in sleep: A clinical population study using the Sleep Disorders Questionnaire.* Sleep 2007;30(3):312–9.

2006-2003

147. Fuhrmann V, Madl C, Mueller C, et al. *Hepatopulmonary Syndrome in Patients With Hypoxic Hepatitis.* Gastroenterology 2006;131(1):69–75.
148. Kramer L, Hofer H, Bauer E, et al. *Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection.* AIDS 2005;19(Suppl 3):S85–92.
149. Prebio M, Katz-Papatheophilou E, Heindl W, Gelbmann H, Burghuber OC. *Verminderung von hautdefekten bei bauchlagerung bei beatmeten intensivpatienten durch das prone-head-support-system: Eine pilotstudie.* Wien Klin Wochenschr 2005;117(3):98–105.
150. Valipour A, Kreuzer A, Koller H, Koessler W, Burghuber OC. *Bronchoscopy-Guided Topical Hemostatic Tamponade Therapy for the Management of Life-Threatening Hemoptysis.* Chest 2005;127(6):2113–8.
151. Valipour A, Schneider F, Kössler W, Saliba S, Burghuber OC. *Heart rate variability and spontaneous baroreflex sequences in supine healthy volunteers subjected to nasal positive airway pressure.* J Appl Physiol 2005;99(6):2137–43.
152. Alt E, Amann-Vesti BR, Madl C, Funk G, Koppensteiner R. *Platelet aggregation and blood rheology in severe sepsis/septic shock: relation to the Sepsis-related Organ Failure Assessment (SOFA) score.* Clin Hemorheol Microcirc 2004;30(2):107–15.
153. Hartl S, Heindl W, Lahrmann H, et al. *Provisions for long-term at home ventilated patient: consensus recommendations of the Austrian Society for Lung Diseases and*

Tuberculosis. Wien Klin Wochenschr 2004;116 Suppl(3):1–20.

154. Valipour A, Cozzarini W, Burghuber OC. *Non-Invasive Pressure Support Ventilation in Patients with Respiratory Failure due to Severe Acute Cardiogenic Pulmonary Edema*. Respiration 2004;71(2):144–51.
155. Valipour A, Litschauer B, Mittermayer F, Rauscher H, Burghuber OC, Wolzt M. *Circulating plasma levels of vascular endothelial growth factor in patients with sleep disordered breathing*. Respir Med 2004;98(12):1180–6.
156. Bauer E, Funk G-C, Gendo A, et al. *Electrophysiological assessment of the afferent sensory pathway in cardiac arrest survivors*. Eur J Clin Invest 2003;33(4):283–7.
157. McGown AD, Makker H, Elwell C, Rawi PG Al, Valipour A, Spiro SG. *Measurement of Changes in Cytochrome Oxidase Redox State During Obstructive Sleep Apnea Using Near-Infrared Spectroscopy*. Sleep 2003;26(6):710–6.
158. Petkov V, Mosgoeller W, Ziesche R, et al. *Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension*. J Clin Invest 2003;111(9):1339–46.
159. Stiebellehner L, Petkov V, Vonbank K, et al. *Long-term Treatment With Oral Sildenafil in Addition to Continuous IV Epoprostenol in Patients With Pulmonary Arterial Hypertension*. Chest 2003;123(4):1293–5.

Reviews, editorials, guidelines, books

1. Ariel A, Altraja A, Belevskiy A, et al. Inhaled therapies in patients with moderate COPD in clinical practice: Current thinking. *Int J COPD* 2018;13:45–56.
2. Urban M, Burghuber OC. Chronisch obstruktive Lungenerkrankung (COPD). *Wiener Klin Wochenschrift Educ* 2018;13(1–4):29–47.
3. Valipour A. Bronchoscopic Thermal Vapour Ablation: Hot Stuff to Treat Emphysema Patients! *Arch Bronconeumol* 2017;53(1):1–2.
4. Schenk P, Eber E, Funk G-C, et al. Nichtinvasive und invasive außerklinische Beatmung beim chronisch respiratorischen Versagen. *Wien Klin Wochenschr* 2016;128(S1):1–36.
5. Valipour A, Burghuber OC. An update on the efficacy of endobronchial valve therapy in the management of hyperinflation in patients with chronic obstructive pulmonary disease. *Ther Adv Respir Dis* 2015;9(6):294–301.
6. Virchow JC, Akdis CA, Darba J, et al. A review of the value of innovation in inhalers for COPD and asthma. *J Mark Access Heal Policy* 2015;3(1):28760.
7. Burghuber OC, Urban MH, Hartl S. Lungenkrankheiten im Zusammenhang mit dem Rauchen (außer Lungenkrebs und COPD). *Atemwegs- und Lungenkrankheiten* 2015;41(8):364–71.
8. Valipour A. Ambulatory management of primary spontaneous pneumothorax: the good is (not always) the enemy of the better (evidence). *Eur Respir J* 2014;43(2):334–6.
9. Valipour A, Slebos D-J, de Oliveira HG, et al. Expert Statement: Pneumothorax Associated with Endoscopic Valve Therapy for Emphysema - Potential Mechanisms, Treatment Algorithm, and Case Examples. *Respiration* 2014;87(6):513–21.
10. Breyer M-K. Adiposity in COPD. Maastricht University, the Netherlands; 2013.
11. Hartl S, Netz M, Breyer M-K, Breyer-Kohansal R. Husten – Atemnot – COPD. *Med Media Verlag*; 2012.
12. Valipour A. Pros and Cons of Humidification for CPAP Therapy in the Treatment of Sleep Apnea [Internet]. In: Esquinas Rodriguez AM, editor. *Humidification in the Intensive Care Unit*. Berlin, Heidelberg: Springer Berlin Heidelberg; 2012. p. 109–13.
13. Burghuber OC, Breyer M, Funk G, Vogelmeier C. Komorbiditäten bei COPD – Entzündung und antiinflammatorische Therapie. *Bremen, London, Boston: Uni-Med*; 2012.
14. Valipour A. Kardiale Komorbidität bei COPD. *Atemwegs- und Lungenkrankheiten* 2011;2(37):48–50.

15. Esquinas Rodriguez AM, Scala R, Soroksky A, et al. Humidifiers during non-invasive ventilation - key topics and practical implications. *Crit Care* 2011;16(1):203.
16. Hartl S. Chronic Obstructive Pulmonary Disease Exacerbations: Better Standards – Better Prognosis? *Respiration* 2011;82(4):317–9.
17. Valipour A, Burghuber OC. Schlafatemstörungen. *Wiener Klin Wochenschrift Educ* 2009;4(1):15–32.
18. Burghuber OC, Valipour A. Knowing chronic obstructive pulmonary disease by heart: Cumulating evidence of systemic vascular dysfunction. *Am J Respir Crit Care Med* 2009;180(6):487–8.
19. Burghuber OC, Valipour A. Knowing Chronic Obstructive Pulmonary Disease by Heart. *Am J Respir Crit Care Med* 2009;180(6):487–8.
20. Hartl S, Breyer M. Nicht invasive Beatmung (NIV). *Wiener Klin Wochenschrift Educ* 2009;4(3):113–21.
21. Wouters EFM, Celis MPM, Breyer MK, Rutten EPA, Graat-Verboom L, Spruit MA. Co-morbid manifestations in COPD. *Respir Med COPD Updat* 2007;3(4):135–51.
22. Hartl S, Schmidt I. Atemphysiotherapie bei CVI unter Berücksichtigung der NIV – Optionen. In: Schönhofer B, editor. *Nicht-invasive Beatmung - Grundlagen und moderne Praxis*. Bremen, London, Boston: Uni-Med; 2006. p. 178–81.
23. Hartl S, Burghuber OC. The diagnosis of COPD. *Wien Klin Wochenschr* 2005;155(5–6):90–4.
24. Burghuber OC. Editorial Chronisch obstruktive Lungenerkrankung. *Wien Klin Wochenschr* 2005;155(5–6):77–77.
25. Schenk P, Stiebellehner L, Burghuber OC, Kneussl M, Lang IM. Untersuchung des Lungenkreislaufes mittels Rechtsherzkatheter: Positionspapier des Kardiopulmonalen Arbeitskreises der Österreichischen Gesellschaft für Pneumologie und der Österreichischen Gesellschaft für Kardiologie. *Wien Klin Wochenschr* 2005;117(18):651–62.
26. Burghuber OC. COPD - State of the Art. *Osterr Arzteztg* 2005;9.
27. Burghuber OC. Pulmonary embolism: Clinical features. In: Albert A, Spiro S, Jett J, editors. *Clinical Respiratory Medicine*. Mosby; 2004.
28. Block LH, Burghuber OC, Hartl S, Zwick H, Österreichische Gesellschaft für Lungenerkrankungen und Tuberkulose. Österreichische Gesellschaft für Lungenerkrankungen und Tuberkulose: Konsensus zum Management der chronisch obstruktiven Lungenerkrankungen (COPD). *Wien Klin Wochenschr* 2004;116(7–8):268–78.

29. Valipour A, Burghuber O. Non-invasive pressure support ventilation in patients with acute cardiogenic pulmonary edema: a critical appraisal. In: Esquinas A, Volsko T, Scala R, editors. *International Respiratory Care Clinics and Technology*. Mason / Grupo Aulamedica; 2003.
30. Koller HK, Burghuber OC. Diffuse interstitielle Lungenerkrankungen mit besonderer Berücksichtigung des rheumatischen Formenkreises. *Z Rheumatol* 2003;62(2):122–35.
31. Block LH, Burghuber OC, Hartl S, Zwick H. Konsensus-Empfehlungen der Arbeitsgruppe Pulmonalarterielle Hypertension der Österreichischen Gesellschaft für Lungenerkrankungen und Tuberkulose. *Wien Klin Wochenschr* 2003;115(10):351.
32. Pirker R, Prosch H, Popper H, Klepetko W, Dieckmann K, Burghuber OC, Klikovits T, Hoda MA, Zöchbauer-Müller S, Filipits M. Lung Cancer in Austria. *J Thorac Oncol*. 2021 May;16(5):725-733. PMID: 33896572.
33. Agusti A, Breyer-Kohansal R, Faner R. Transitioning from infancy to adulthood: a black box full of opportunities. *Eur Respir J*. 2021 Mar 4;57(3):2003997. doi: 10.1183/13993003.03997-2020. PMID: 33664098.